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Thrombospondin-1 (TSP-1) is involved in a variety of diﬀerent cellular processes including cell adhesion, tumor progression, and
angiogenesis. This paper reports the novel ﬁnding that TSP-1 upregulates integrin α6 subunit in human keratinocytes and human
breast cancer cells resulting in increased cell adhesion and tumor cell invasion. The eﬀect of TSP-1 on α6 subunit expression was
examined in human keratinocytes and breast adenocarcinoma cell lines (MDA-MB-231) treated with TSP-1 and in TSP-1 stably
transfected breast cancer cells. TSP-1 upregulated α6 message and protein in these cells as revealed by diﬀerential display, Northern
and Western blot analysis and immunohistochemical localization studies. The increased expression of α6 was shown to mediate
adhesion and invasion of these cells to laminin, a major component of the basement membrane and extracellular matrix (ECM).
ThesedatasuggestthatTSP-1playsanintegralroleintheattachmentofcellstotheECMfacilitatingcellmotilityandangiogenesis.
1.Introduction
Adhesion to extracellular matrix (ECM) proteins is involved
in almost every aspect of tumor cell metastasis including
adhesion of circulating tumor cells in the vascular bed,
invasion through the basement membrane, and growth of
the new metastasis at a distant site [1]. In addition, contact
with the ECM stimulates intracellular signaling, regulating
cellattachment,migration,angiogenesis,andinvasion[2–4].
Cellular adhesion is one of the major functions of
thrombospondin-1(TSP-1),acomponentoftheECM.TSP-1
is a 450kDa glycoprotein, originally thought to be a platelet
α-granule speciﬁc protein [5]. Our laboratory was the ﬁrst
to show that TSP-1 functions both as a tumor cell and
platelet adhesive protein [6]. There are four motifs in TSP-
1 which have been recognized as adhesive domains: (1)
the N-terminal heparin binding domain and its association
with cell surface heparin proteoglycans, (2) the CSVTCG
sequences within the type 1 repeats and its association with
CD36 and the CSVTCG receptor, (3) the RGD sequence
within the type 3 repeats and its association with the αvβ3
integrins, and (4) the RFYVVMWK and IRVVM sequences
in the C-terminal domain [7]. A number of cell types can
attach to TSP-1 including endothelial cells and myoblasts [8–
10].Inaddition,manytumorcelltypessuchasosteosarcoma
cells, melanoma cells, and breast cancer cells also adhere
to TSP-1 [11–13]. This suggests that TSP-1 attachment can
facilitate movement through the ECM.
There are several integrins that bind TSP-1. The best
characterized interaction is with αvβ3 integrin and TSP-1,
resulting in adhesion of a variety of cell types including
platelets, melanoma cells, endothelial cells, and smooth
muscle cells [14]. Other integrins that serve as TSP-1
receptors include αIIbβ3, α2β1, α3β1, α4β1, α9β1,a n dα6β1
[15].
Integrins are a family of cell surface glycoproteins
that function as receptors for ECM proteins, mediating
both cell-substratum and cell-cell adhesion. Integrins are
noncovalent, heterodimeric complexes of an α subunit and
a β subunit [16]. To date there are 18α and 8β subunits
which can associate to form at least 24 heterodimers [17, 18].
Because integrins play a major role in cell adhesion, it is2 Journal of Oncology
not surprising that there is frequently altered expression
and function of integrins in various tumor types [19].
Speciﬁcally, the α6 integrins have higher levels of expression
in squamous carcinoma, small cell lung carcinoma, and
bladder cancer [20]. Increased integrin α6β4l e v e l sh a v ea l s o
beenassociatedwithadecreasedsurvivalrateinpatientswith
bladder cancer [21]. In addition, there has been evidence
that integrin α6 expression is necessary for the tumor-like
properties of a breast cancer stem cell like subpopulation
[22].
Although the involvement of TSP-1 and integrins thus
far are that of ligand and receptor, in this study, we report
for the ﬁrst time that TSP-1 is capable of upregulating
α6 expression in breast adenocarcinoma cells. Through
diﬀerential display analysis, we determined TSP-1 stimulated
increased α6 mRNA levels in human keratinocytes. Given
TSP-1 promotes metastasis and integrin α6 expression and
function is abnormal in tumor cells, we then examined
the eﬀect of TSP-1 on integrin α6 expression in breast
adenocarcinoma cell lines MDA-MB-231 and MDA-MB-
435. Subsequent adhesion and invasion assays demonstrate
a functional signiﬁcance of this α6 expression with increased
adhesion and increased tumor cell invasion. We hypothesize
that TSP-1 not only acts as an adhesive protein itself, but also
facilitates the adhesion of tumor cells to other extracellular
matrix proteins, via upregulation of integrin α6 expression.
Ourresultsnotonlyapplytobreastcancertumorigenesisbut
mayhaveadirectbearingonTSP-1-mediatedmechanismsof
tumor angiogenesis.
2.MaterialsandMethods
2.1. Materials. All reagents, unless speciﬁed otherwise, were
reagent grade and purchased from Sigma Chemical Co. (St.
Louis, MO). Tissue culture supplies were purchased from
FisherScientiﬁc(Malvern,PA).ReagentsforSDS-PAGEwere
purchased from Bio-Rad Laboratories (Richmond, CA).
Laminin (type 1), type IV collagens and ﬁbronectin were
purchased from Collaborative Research (Bedford, MA). Rat
monoclonal anti-integrin α6 (clone NK1-GoH3) and mouse
monoclonal anti-integrin α6 (clone 1A10), prepared against
a C-terminal peptide of the α6 heavy chain were purchased
from Chemicon (Millipore/Chemicon, Billerica, MA). Goat
polyclonal antihuman TSP-1 IgG and mouse monoclonal
antihuman TSP-1 were made in our laboratory.
2.2. Boyden Chamber Invasion Assay. Breast tumor cell
invasion was measured using the modiﬁed Boyden chamber.
Polycarbonate ﬁlters, 8μm pore size (Millicell, Millipore
Corporation, Bedford, MA), were coated with 100μgt y p e
IV collagen (1mg/mL 60% EtOH) and dried overnight at
25
◦C. Blind-well Boyden chambers were ﬁlled with 700μL
of serum-free media containing 0.1% BSA in the lower
compartment, and the coated ﬁlters were mounted in the
chamber. Approximately 50,000 cells (tested to be greater
that95%viable)suspendedin300μLofthesamemediawere
placed in the upper chamber of the apparatus and allowed
to settle onto the collagen-coated membrane. TSP-1 at a
concentrationof133nM(60μg/mL)wasaddedinserumfree
media containing 1% albumin in the lower chamber and any
neutralizing antibodies (10μg/mL IgG) as well as peptides
were placed in the upper chamber. After an incubation
period of 3–6h at 37
◦C, the cells on the upper surface of the
ﬁlter were removed with a cotton swab. The ﬁlters were ﬁxed
in 3% glutaraldehyde solution and stained with 0.5% crystal
violet solution. Invasive cells adhering to the under-surface
of the ﬁlter were counted using a phase contrast microscope
(400X). The data were expressed as the summation of the
number of invasive tumor cells in ﬁve representative ﬁelds.
2.3. Cell Culture and Treatment. The human breast adeno-
carcinoma cell line MDA-MB-231 was purchased from the
American Type Culture Collection (CRL 10317, Rockville,
MD). The TSP-1-transfected breast adenocarcinoma cell
lines derived from MDA-MB-435 cells were obtained from
Dr. David Roberts, NCI. These include three lines: a vector
control (TH5), an intermediate TSP-1 producer (TH29),
a high TSP-1 producer (TH26), and a carboxyl terminal
truncated TSP-1 producer (TH50). The origin of the MDA-
MB-435 cell line has been in question with some studies
suggesting that the line was identical to a M14 melanoma
line, however recent published data is consistent with both
M14 and MDA-MB-435 cell lines being of breast cancer
origin [23, 24]. Primary keratinocytes were obtained from
Dr. Vicki Werth at the University of Pennsylvania and grown
in keratinocyte media (Sigma Chemical Co). All cultures
were kept in 5% CO2 at 37
◦C. Cells were cultured in 6-well
platesforintegrinα6stainingorT75ﬂasksforRNAisolation.
Cells were grown to 85% conﬂuence and were washed and
incubated in serum-free medium containing 0.1% BSA.
Diﬀerent concentrations of TSP-1 and/or antibodies or
peptides were added for a 1 to 72h incubation. Cell viability
after treatments was monitored by the trypan blue exclusion
assay.
2.4. Cell Adhesion Assay. Wells of ninety-six well plates were
coated with 0.1mL of either 50μg/mL laminin, 50μg/mL
collagentypeIV ,or1%BSAfor60minutesat37
◦C.Thewells
were aspirated, treated with 200μL PBS containing 1% BSA
for 1 hour and washed three more times with 200μL of PBS.
Cells were incubated in TSP-1 or control buﬀer for 24 hours
before being harvested. Cells were harvested and washed
two times in serum-free DMEM and suspended in DMEM
with the appropriate treatment at a ﬁnal concentration of
5 × 104 cells/100μL. Aliquots of 100μL were added to the
wells and incubated at 37
◦C for 60 minutes or until cells
have attached and spread. Nonadherent cells were removed
by aspiration and the wells were washed three times with
PBS.Thetotalcellassociatedproteinwasdetermineddirectly
by dissolving the attached cells in the microtiter wells with
200μL of the Pierce BCA working solution. The plate was
covered with an adhesive mylar sheet and incubated at 60
◦C
for 30 minutes. After cooling to room temperature and
removing cover sheets, the absorbance of each well was
measured at 562nm with a microtiter plate reader (Biotek,
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2.5. Diﬀerential Display. One one-base anchored oligodeoxy
thymidylic acid primer HT11G (5 -AAGCTTTTTTTT-
TTTG-3 )w a su s e dt or e v e r s et r a n s c r i b em R N Af r o m
keratinocytes into ﬁrst-strand cDNA, which was ampliﬁed
subsequently by PCR using the arbitrary upstream primers
H-AP5 (5 -AAGCTTAGTAGGC-3 ) and H-AP8 (5 -AAG-
CTTTTACCGC-3 ). Protocols were followed as described
by Liang and Pardee [25] .P C Rp r o d u c t sw e r ea n a l y z e do n
a 6% DNA sequencing gel. The bands that showed either
upregulation or downregulation were cut out from the gel,
eluted, and ampliﬁed by PCR.
2.6. Cloning and Sequencing. The reampliﬁed cDNA bands
were cloned using the TA cloning kit (Invitrogen, SanDiego,
CA). The isolated fragment was sequenced using an auto-
mated DNA sequencer (Core Sequencing Facility, Drexel
School of Medicine). The sequence was then analyzed
through an NCBI Blast search.
2.7. Immunohistochemical Staining. The rat antihuman inte-
grin α6 antibody, GoH3, was used for cell staining. Rat IgG
controls were used. TSP-1-transfected cell lines and MBA-
MD-231 cells treated with exogenous TSP-1 were grown
to 85% conﬂuence on glass slides. The cells were then
ﬁxed with 2.5% glutaraldehyde and stained with the avidin-
biotin immunoperoxidase complex technique (Vectastain
Elite ABC Kit, Vector Laboratories).
2.8. Northern Blot Analysis. Total RNA was isolated from
tumor cells by Rneasy Total RNA Kits (QIAGEN Inc.
Chatsworth, CA) following the manufacturer’s direction.
15μg of total RNA was subjected to electrophoresis on 1%
agarose/formaldehydegelsandblottedontonylonpaper.The
paper was hybridized with the appropriate 32P-labeled cDNA
probes and autoradiographed at −80
◦C with an intensifying
screen. After recording the results, the same paper was re-
probedwithabeta-actincDNAprobeandexposedat −80
◦C.
The cDNAs were radiolabeled with 32P by the random
primer labeling method using the Stratagene labeling kit
(Stratagene, La Jolla, CA).
2.9. Thrombospondin-1 Puriﬁcation. TSP-1 was puriﬁed
from Ca+2 ionophore A23187-activated platelets in our
laboratory as previously described [26]. Purity was assessed
by SDS-PAGE using Coomassie blue or silver staining. All
TSP-1 used was further puriﬁed to remove all bound TGF-
β1 according to the procedure of Murphy-Ullrich et al. [27].
TGF-β1 levels were monitored by human TGF-β1 ELISA kits
(Quantikine, R&D Systems, Minneapolis, MN).
2.10. Western Blot Analysis. Total SDS-detergent lysate of
breast cancer cells was fractionated on a 10% SDS-PAGE and
then transferred to a PVDF membrane using a Pharmacia
Phast gel electrophoresis system. Nonspeciﬁc sites of the
membranes were blocked with 5% skim milk in Tris-
buﬀered saline containing 0.1% Tween 20 (TBS-T) for 1h.
The immunoblots were incubated with primary antibodies
diluted in TBS-T for 1 h at a concentration of 1μg/mL.
Lanes 1-4:
buﬀer control
Lanes 5-8:
TSP-1 treated
α6 integrin
12345678
(a)
α6 integrin
Buﬀer TSP-1
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Figure 1: TSP-1 upregulates integrin α6 subunit message in
human keratinocytes. Keratinocytes were treated with either bis-
tris-propane buﬀer or TSP-1 (60μg/mL) in serum-free media and
mRNA expression was analyzed by (a) diﬀerential display analysis
and conﬁrmed with (b) northern blot analysis. Experiments were
repeated three times and the results of a representative experiment
are shown in the ﬁgure.
After washing, the immunoblots were incubated in TBS-
T with the appropriate horseradish peroxidase-conjugated
secondary antibodies for 1h at a concentration of 0.1μg/mL.
The immunoreactivity was detected using enhanced chemo-
luminesence (ECL) system (Amersham, Arlington Heights,
IL).
3. Results
3.1. Identiﬁcation of α6 Upregulation. Diﬀerential display
analysis was performed on keratinocytes treated with either
20mM bis-tris propane buﬀer (vehicle for TSP-1) or TSP-
1( 6 0μg/mL) for twenty-four hours. The mRNA from these
cells was collected and used for diﬀerential display RT-PCR.
Several bands were found to be upregulated (Figure 1(a))
between buﬀer and TSP-1-treated samples in two separate
mRNA samples collected from independent experiments.
TheupregulationofonebandwasconﬁrmedusingNorthern
blot analysis (Figure 1(b)). The isolated band (236bp) was
clonedandsequencedandwasfoundtoshow98%homology
to the integrin α6 subunit.
3.2. The Eﬀect of TSP-1 on Integrin α6 mRNA Production in
H u m a nB r e a s tC a n cerC ell s . To examine if TSP-1 upregulates
integrin α6p r o d u c t i o ni nh u m a nb r e a s tc a n c e rc e l l s ,M D A -
MB-231 cells were treated with TSP-1 (60μg/mL) and
total RNA was collected at various time points including
1 hour, 6 hours, 12 hours, and 24 hours. The 236 base
pair band isolated through diﬀerential display was used as
the probe for northern blot analysis. The results show that
integrin α6 expression appears to increase after a 24 hour
incubation with TSP-1 with some downregulation seen at
the one hour time point (see Figure 2(b)). In addition, TSP-
1 stably transfected MDA-MB-435 cells were also examined4 Journal of Oncology
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Figure 2: TSP-1 induces integrin α6 mRNA expression in human
breast cancer cells. Two breast cancer cell lines (a) stably transfected
TSP- 1 MDA-MB-435 cell lines with variable TSP-1 expression
and (b) MDA-MB-231 cells treated with either buﬀer or TSP-1
(60μg/mL) were analyzed by northern blot analysis for integrin α6
expression. TSP-1 dose dependent response of integrin α6w a st h e n
assessed in the MDA-MB-231 (c). Blots were normalized to a 2.4
β-actin probe. A pancreatic carcinoma cell line, BxPC3, was used as
apositivecontrol.(a)TSP-1stablytransfectedTSP-1cells.1:BxPC3
cell line, 2: TH5 cells (vector control), 3: TH29 cells (intermediate
TSP-1 producer), and 4: TH26 cells (high TSP-1 producer). (b)
MDA-MB-231 cells. 1: BxPC3 cell line, 2: buﬀe rt r e a t m e n t ,3 :T S P -
1( 1h o u r ) ,4 :T S P - 1( 6h o u r s ) ,5 :T S P - 1( 1 2h o u r s ) ,a n d6 :T S P - 1
(24 hours). Experiments were repeated three times and the results
of a representative experiment are shown in the ﬁgure. (c) MDA-
MB-231 cells. 1: Buﬀer treatment, 2: TSP-1 (20μg/mL), 3: TSP-1
(40μg/mL), and 4: TSP-1 (60μg/mL).
for integrin α6 mRNA expression. Three cells lines were
examined: a vector control (TH5), an intermediate TSP-1
producer (TH29), and a high TSP-1 producer (TH26). The
results show that the highest level of integrin α6m R N A
occurred in the high TSP-1 producer (TH26) (Figure 2(a)).
The intermediate producer showed more integrin α6m R N A
production than the vector control (TH5) but less than the
TH26 cell line. MDA-MB-231 cells were then incubated with
varyingconcentrationsofTSP-1foraperiodof24hours.The
highest level of expression occurred with a TSP-1 dosage of
60μg/mL. This data support the conclusion that TSP-1 not
only upregulates integrin α6 mRNA expression, but that it
does so in a dose and time dependent fashion.
3.3. Expression of Integrin α6 Protein in Human Breast
Carcinoma Cell Lines. MDA-MB-231 cells were treated with
either buﬀer or TSP-1 (60μg/mL) for 24 hours and the
cells were lysed with SDS-PAGE sample buﬀer and analyzed
for α6 protein expression by Western blot analysis. The
TSP-1-treated cells expressed a signiﬁcant increase in a
120 kilodalton band consistent with the heavy chain of
the α6 subunit (Figure 3(a)). A slightly smaller band of
approximately 115 kilodaltons was also seen in the blot
consistentwiththepresenceofasplicevariantordegradation
product of the α6 subunit. Similarly, when the blot of the
whole cell lysate of the TSP-1 stably transfected breast cell
line, TH26, was compared to the vector control TH5, we
saw a marked expression of 90 and 120 kilodalton bands
when the blots were probed with an antibody speciﬁc for
the heavy chain of the α6 subunit (Figure 3(b)). The blots
were also probed with an antibody to TSP-1 conﬁrming that
eitherTSP-1wasaddedexogenouslyorthatthecellexpressed
their own TSP-1 (second panel in Figures 3(a) and 3(b)).
Equal loading of the samples was conﬁrmed by probing the
extracts with an antibody to β-actin. These results conﬁrm
the Northern Blot results indicating that TSP-1 not only
upregulates integrin message but also protein.
To further show that α6 expression is dependent on
TSP-1 expression, the panel of TSP-1 expressing cells were
ﬁxed with 2.5% gluteraldehyde and immunohistochemically
stained with a rat monoclonal antibody speciﬁc against the
heavy chain of α6( Figure 4). When the TSP-1 transfected
cell lines TH29, TH26 and TH50 were examined, only TH29,
and TH26 showed signiﬁcant expression of α6, while the
vectorcontrollineTH5andTH50cellline,expressingaTSP-
1mutantmissingthecarboxylterminuswerenegative.These
resultsshowthatα6expressionisdependentonexpressionof
full-length TSP-1.
3.4. Establishing Speciﬁcity of TSP-1-Induced Integrin α6
Expression. To determine if the staining observed in the
stably transfected cells was speciﬁc to TSP-1, the TH26
cells were treated with either 10μg/mL of polyclonal goat
anti-TSP-1 IgG or 10μg/mL of goat IgG and grown for an
additional 24 hours. Immunohistochemical staining showed
decreased expression of integrin α6 in the TH26 cells treated
with the anti-TSP-I IgG comparable to the TH5 vector
control, while the control antibody IgG-treated cells and
untreated cells showed signiﬁcant α6 staining (Figure 5).
When the same experiment was repeated using an antitype 1
repeat TSP-1 antibody, there was no blocking eﬀect (data not
shown). These results suggest that endogenously produced
TSP-1 speciﬁcally induces integrin α6 upregulation through
domains other than the type 1 repeat domain of TSP-1.
3.5. The Functional Signiﬁcance of TSP-1-Induced Integrin α6
Expression on Tumor Cell Adhesion. TSP-1 stably transfected
breast cancer cell lines were tested for adhesion to laminin,
the major adhesive ligand of α6β1( Figure 6). We found that
only the high TSP-1 expressing cell line TH26 showed a
signiﬁcantly higher (>50%) extent of adhesion to laminin
(P<. 05), when compared to either the vector control
line TH5 or TH50, line expressing the carboxyl domain-
truncated TSP-1 (Figure 6(a)). The TH29 cell line also had a
signiﬁcantly higher level of adhesion to laminin as compared
to BSA (P<. 05), but the results were not as impressive as
the high TSP producing cell line (TH26). Adhesion of TH5Journal of Oncology 5
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Figure 3: TSP-1 induces integrin α6 protein expression in human breast cancer cells. MD-MBA-231 cells (a) and MD-MBA-435 cells (b)
were grown in six well tissue culture plates in serum-free media either with or without 60μg/mL TSP-1 for 24 hours. Cell extracts were
prepared with SDS-sample buﬀer, reduced with 5% β-mercaptoethanol, and separated on 10% SDS-PAGE. Blots were probed with 1μg/mL
of mouse α6 integrin IgG and followed by 0.1μg/mL HRP-coupled rabbit antimouse IgG and developed using enhanced chemoluminesence.
Experiments were repeated two times and the results of a representative experiment are shown in the ﬁgure.
(a) (b)
(c) (d)
Figure 4: TSP-1 stably transfected cells express integrin α6. Cells were grown in six well chamber slides, ﬁxed, and stained with rat α6
integrin IgG as described in Section 2. Cells were photographed at 200X magniﬁcation. (a) TH5 cells (vector control). (b) TH29 cells, (c)
TH50, (d) TH26 cells. Experiments were repeated three times and the results of a representative experiment are shown in the ﬁgure.
and TH50 cell lines to laminin were statistically the same and
statisticallyindistinguishable fromadhesion tobovine serum
albumin (BSA), the negative control (Figure 6(a)).
To show that the adhesion of TH26 cell line to laminin
was TSP-1 and α6-integrin dependent, blocking experiments
with either a polyclonal TSP-1 antibody or an anti-integrin
α6 monoclonal were performed (Figures 6(b) and 6(c)).
When TH26 cells were preincubated for 24 hours with either
10μg/mL of polyclonal goat anti-TSP-1 IgG or 10μg/mL of
rat monoclonal anti-integrin α6 (clone NK1-GoH3) IgG,
adhesion of the cells was reduced to levels observed with the
vector control line THP5 (Figures 6(b) and 6(c)). In contrast
the respective control IgGs had no eﬀect on adhesion and
theextentofadhesionwasstatisticallyindistinguishablefrom
untreated cells (compare bar labeled cells alone with bar
labeled cell plus IgG, P>. 5, in Figures 6(b) and 6(c),r e s p . ) .
These results strongly suggest that that adhesion of TH26
cells to laminin is dependent on both TSP-1 and integrin α6.6 Journal of Oncology
(a) (b)
(c) (d)
Figure 5: Anti-TSP-1 antibody inhibition of integrin α6 production in TSP-1 stably transfected cells. Cells were grown in six well chamber
slidesineitherserum-freemediaormediacontainingeither10μg/mLcontrolIgGor10μg/mLgoatantihumanTSP-1IgG,ﬁxed,andstained
with rat α6 integrin IgG as described in Section 2. Cells were photographed at 200X magniﬁcation. (a) TH5 cells (vector control). (b) TH26
cells (high TSP-1 producer). (c) TH26 cells plus anti-TSP-1 antibody. (d) TH26 cells plus control IgG.
3.6. The Eﬀect of TSP-1-Induced Integrin α6 Expression in
Tumor Cell Invasion through Laminin. Tumor cell invasion
of laminin was dependent on TSP-1 and α6β1 expression
(Figure 7). After ﬁve hours of incubation, the high TSP-1
producer cell line TH26 was 5-fold more invasive than either
the TH5 vector controls or TH50 cells expressing carboxyl
truncated TSP-1 (Figure 7(a)). Using a six-hour incubation
period, the experiment was repeated in the presence of either
10μg/mL of polyclonal goat anti-TSP-1 IgG or 10μg/mL
of rat monoclonal anti-integrin α6 (clone NK1-GoH3) IgG
(Figure 7(b)). At baseline, again the TH26 cells showed 5-
fold more invasion than the TH5 cells. Incubating the TH26
cellswitheitherapolyclonalTSP-1antibodyoraneutralizing
integrin α6 antibody completely reduced invasion to the
level of the TH5 cells. Taken together, these data provide
strong evidence that tumor cell adhesion and migration are
inﬂuenced by TSP-1-mediated integrin α6 expression and
are consistent with our previous studies showing that TSP-1
promotes the invasion of breast cancer cells [13].
4. Discussion
TSP-1 expression has been examined quite extensively in
a variety of tumor types. TSP-1 localizes strongly in the
desmoplastic stroma surrounding the tumor in head and
neck cancers, pancreatic cancer, and breast carcinoma [28].
In addition, a variety of tumor cells are capable of secreting
TSP-1 including pancreatic tumor cells, squamous lung
carcinoma, and breast cancer cells [7]. TSP-1 is involved in
both tumor cell adhesion and tumor cell invasion through
multiple mechanisms including several adhesive domains
within TSP-1 itself and upregulation of enzymes such as
matrix metalloproteinase 9 (MMP-9) [29, 30].
This report describes the novel observation that TSP-1
stimulatesintegrinα6expressioninhumanbreastcarcinoma
cells. Although TSP-1 and integrins have been studied, the
relationship thus far described has been that of receptor and
ligand. We have discovered through diﬀerential display that
T S P - 1i sa b l et ou p r e g u l a t ei n t e g r i nα6 message in human
keratinocytes. When we subsequently examined two human
breast cancer lines, the MDA-MB-231 cell line and a TSP-1
stably transfected MDA-MB-435 cell line, integrin α6m R N A
expression increases with both exogenous treatment and
endogenous expression of TSP-1. Western blot analysis with
anti-α6 antibody of breastcancercellsstablytransfectedwith
TSP-1 or cells treated with TSP-1 revealed the upregulation
of bands of 80–120kDa consistent with the heavy chain
of α6 subunit. In addition, immunohistochemical analysis
of the TSP-1 stably transfected cells showed that the high
TSP-1 producers (TH26) were positive for integrin α6
protein expression as compared to the vector control (TH5),
the intermediate TSP-1 producer (TH29), or the carboxyl
terminally truncated TSP-1 producer (TH50). Repeating the
staining after treating with anti-TSP-1 polyclonal antibodies
resulted in markedly decreased expression of integrin α6
protein to the level of the TH5 cells. As stated above, TSP-
1 is not only produced by tumor cells but also by cells within
the tumor stroma, such as ﬁbroblasts. This upregulation
of integrin α6 by TSP-1, both exogenous and endogenous,
suggests that TSP-1 contributes to tumor cell adhesion by
both direct production by tumor cells and by exposure to
exogenous TSP-1 within the desmoplastic stroma. Potential
therapeutics will need to target not only TSP-1 within the
extracellular matrix, but also that produced by the tumor cell
itself. These results indicate that TSP-1 upregulates integrin
α6proteinbothatthemessageandproteinlevelandisoneofJournal of Oncology 7
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Figure 6: High endogenous TSP-1 production increases cell adhesion to laminin. Stably transfected MDA-MB-435 cells were either
incubated alone (a), with either 10μg/mL control IgG or 10μg/mL goat antihuman TSP-1 IgG (b), or either 10μg/mL control IgG or
10μg/mL rat antihuman α6 integrin IgG (c), and assessed for adhesion to laminin as described in Section 2.B S Aw a su s e da san e g a t i v e
control. The error bars represent the standard error of the mean of triplicate samples and the experiment was repeated three times with
similar results.
the matrix proteins involved in tumor cell regulation of cell
surface receptors needed for tumor progression.
The functional signiﬁcance of TSP-1’s eﬀect on stimu-
lating integrin α6 production was examined through both
cell adhesion and cell invasion assays. When examining the
stably transfected cells in a cell adhesion assay, the TH26
cells showed a signiﬁcantly higher level of adhesion than
the TH5 or TH50 cell lines. The intermediate producers of
TSP-1, the TH29 cells, did show an increase in adhesion to
laminin, but not to the same extent as the TH26 cell line.
This reﬂects the dose-dependent eﬀect that TSP-1 has on
integrin α6 mRNA production. This adhesion to laminin
was inhibited by a polyclonal anti-TSP-1 antibody and also
by a monoclonal anti-integrin α6 antibody showing that
both proteins play a role in breast cancer cell adhesion to
laminin, a major component of the basement membrane.
Inhibiting cell adhesion with both antibodies also shows
that the cell adhesion observed was not only due to TSP-
1’s known ability as a promoter of cell adhesion. Certainly,
cell adhesion is a necessary feature of tumor progression and
metastasis. In order for a tumor cell metastasis to occur, the
cell must initially be able to attach to the extracellular matrix
which then serves as a scaﬀold for the tumor to migrate and
eventually invade.
The ability of the TSP-1-transfected breast cancer cells
to invade was also assessed by an in vitro invasion assay.
Invasion was markedly increased in the TH26 cells when
compared to the TH5 cells and the TH50 cells. Neutralizing
antibodies against either TSP-1 or integrin α6w e r ea b l e
to signiﬁcantly reduce invasion through the laminin-coated
ﬁlter. The capacity of the TH26 cells to invade at such a high
rate implies that the expression of the α6 integrins does not
inhibit motility of these cells. In fact, it appears to enhance
motility and invasion likely due to the TSP-1’s known eﬀect8 Journal of Oncology
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Figure 7: High endogenous TSP-1 production increases cell
invasion of laminin. Tumor cell invasion of laminin was performed
as described in Section 2. Invasion of cells untreated (a), invasion
of cells pretreated with either with either 10μg/mL control IgG or
10μg/mLgoatantihumanTSP-1IgGor10μg/mLratantihumanα6
integrin IgG (b). The error bars represent the standard error of the
mean of triplicate samples and the experiment was repeated three
times with similar results.
on upregulating proteolytic systems, such as the matrix
metalloproteinase system and the urokinase system [31, 32].
This, in combination with increased integrin α6p r o d u c t i o n
and TSP-1’s known ability to serve as a cell adhesive protein,
facilitatesboththeattachmentoftumorcellstotheECMand
the migration required for tumor progression.
TSP-1 levels in serum of patients have been shown to
be higher in patients with colorectal cancer with venous
invasion as compared to patients without venous invasion
[33]. A similar study with gynecological malignancies also
showed higher serum levels in patients with cancer and that
TSP-1levelsincreasedwithhighergradesofmalignancy[34].
Asseenwiththecelladhesionassay,TSP-1canhaveavarying
eﬀect depending on the amount produced by the tumor
cell which could account for the more metastatic phenotype
seen in those patients with higher levels of TSP-1. Using
serum levels may also be useful as a biomarker for metastatic
potential. One important aspect of this study not examined
i nd e p t hh e r ei st h eβ subunit association with α6. The α6
subunit is capable of complexing to either the β1 or the β4
subunit although it has been reported to bind the β4 subunit
preferentially [16]. Initial immunoprecipitation experiments
done in our laboratory point to the colocalization of the α6
subunit with the β4 subunit. This data needs to be further
substantiated and is the subject of another study.
The increase in tumor cell invasion seen in the invasion
assay is in part due to TSP-1 upregulation of integrin α6
protein and facilitation of adhesion, but is also due to the
downstream proteolytic systems that are activated by TSP-
1. TSP-1 has been shown to upregulate TGF-β production
which has been shown to be one of the mechanisms for
TSP-1-induced matrix metalloproteinase-9 and urokinase
production [27] .T h e s ep r o t e o l y t i ce n z y m e sh a v eb e e n
shown to be involved in TSP-1-induced tumor cell invasion
[28, 30]. The eﬀects of TSP-1 on cell adhesion through
integrin α6 act in complement with the increased proteolytic
enzymes further facilitating metastasis.
TSP-1 is a complex molecule with multiple mechanisms
of action [29]. These diﬀerent mechanisms are thought to
be mediated by the many diﬀerent domains within the
150kDa TSP-1 molecule. The type 1 repeats in TSP-1 have
been shown to be involved in the regulation of downstream
proteolytic enzymes such as MMP-9 and urokinase, but
in our results, an anti-TSP-1 type 1 repeat antibody was
unable to inhibit expression of TSP-1-induced integrin α6
production as assessed by immunohistochemical staining.
This implies that the type 1 repeats are not responsible for
integrin α6 upregulation, but are important in tumor cell
invasion through stimulating expression ofmatrixdegrading
enzymes. The multiple domains of TSP-1 account for the
multiple mechanisms of action contributing to tumor cell
metastasis, including adhesion to the various components of
the extracellular matrix which is a critical feature of further
metastasis.
In summary, our data show that TSP-1 upregulates
integrin α6 subunit expression both at the message and
protein level in breast cancer cells. This upregulation pro-
motes tumor cell adhesion to laminin, and subsequently
aids in tumor cell invasion. The novel observation that
endogenous TSP-1 is capable of stimulating expression and
possible activation of the α6 integrins warrants further study
especially concerning the mechanisms involved in tumor
progression. The roles of integrin α6 in TSP-1-mediated
eﬀects such as angiogenesis and its interaction with other
TSP-1-mediated proteins are still yet to be determined and
provide an exciting area of new research.
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